RESUMO
BACKGROUND: Peripheral venous access (PVA) devices for apheresis should be selected to provide enough flow with the least vein damage, but little information is available about PVA devices blood flow rates. The aim of this study was to know the blood flow rates provided by the most frequent PVA devices used in apheresis procedures. STUDY DESIGN AND METHODS: An experimental study was designed to simulate a plasma exchange procedure using citrated whole blood (WB). Two steel needles (16- and 17-gauge [G]) and six plastic cannulas (16G, 17G, two 18G, 20G, and 22G) were analyzed. The hematocrit of the WB was adjusted to 45%, 40%, 35%, 30%, and 25%. The separated plasma from the WB was used as replacement fluid. RESULTS: Blood flow rate (inlet/return, mL/min) for 16G and 17G devices with a hematocrit of 45% was 142/142 (maximum admitted by separator); one of the 18G cannulas reached 142/142 and the other one reached 117/140; the 20G cannula reached 78/94; and the 22G reached 45/55. A hematocrit reduction from 45% to 25% increased the flow rate (when possible) over 22% (range: 14%-30%). CONCLUSIONS: PVA devices with a size of 16-18G provided the maximum flow admitted by the apheresis system. The 20G provided flow rates for a significant number of procedures, and 22G could be used in some procedures. The hematocrit should be taken into account when selecting the PVA device since, at hematocrit of 25%, the flow can be from 14% to 30% higher than flow rates reached with blood at hematocrit of 45%.
Assuntos
Remoção de Componentes Sanguíneos , Velocidade do Fluxo Sanguíneo/fisiologia , Hematócrito , Humanos , AgulhasRESUMO
INTRODUCTION: Collection efficiency (CE1) of cells refers to the number of cells that are collected from the total number of cells processed by the apheresis device. Limited data are available about the CE1 of cells when performing leukocytapheresis in nonmobilized donors for cellular therapy purposes. The aim of our study was to evaluate donor- and procedure-related characteristics that might influence the CE1 of cells. MATERIAL AND METHODS: Variables that predicted the CE1 of cells were analyzed by longitudinal linear regression in a series of 1071 leukocytapheresis procedures on 249 nonmobilized donors. Donor-related characteristics considered were gender, age, total blood volume, and complete blood count (CBC) data. Procedure-related characteristics considered were vascular access and device used. RESULTS: Older donor age was associated with a decrease in the CE1 of leukocytes, lymphocytes, monocytes, and mononuclear cells (MNCs; sum of leukocytes and monocytes) and with an increase in the CE1 of platelets (P < .05). Preprocedure CBC data (leukocytes, lymphocytes, monocytes, and platelets) were associated with either a statistically significant increase or decrease in the CE1 of cells. Central line used as vascular access was associated with a statistically significant decrease in the CE1 of MNCs (P = .02). CONCLUSION: Donor's age, preprocedure CBC data as well as central line used as vascular access were factors associated with CE1 of cells. Knowing these characteristics is helpful in the apheresis unit when designing cellular therapy protocols in order to maximize the CE1 of the desired cell and to personalize collection variables for each donor.
Assuntos
Terapia Baseada em Transplante de Células e Tecidos/métodos , Leucaférese/métodos , Adulto , Fatores Etários , Contagem de Células Sanguíneas , Doadores de Sangue , Coleta de Amostras Sanguíneas/normas , Cateterismo Venoso Central , Feminino , Humanos , Leucaférese/normas , Masculino , Fatores SexuaisRESUMO
INTRODUCTION: A therapeutic apheresis (TA) database helps to increase knowledge about indications and type of apheresis procedures that are performed in clinical practice. The objective of the present report was to describe the type and number of TA procedures that were performed at our institution in a 10-year period, from 2007 to 2016. MATERIAL AND METHODS: The TA electronic database was created by transferring patient data from electronic medical records and consultation forms into a Microsoft Access database developed exclusively for this purpose. Since 2007, prospective data from every TA procedure were entered in the database. RESULTS: A total of 5940 TA procedures were performed: 3762 (63.3%) plasma exchange (PE) procedures, 1096 (18.5%) hematopoietic progenitor cell (HPC) collections, and 1082 (18.2%) TA procedures other than PEs and HPC collections. The overall trend for the time-period was progressive increase in total number of TA procedures performed each year (from 483 TA procedures in 2007 to 822 in 2016). The tracking trend of each procedure during the 10-year period was different: the number of PE and other type of TA procedures increased 22% and 2818%, respectively, and the number of HPC collections decreased 28%. CONCLUSION: The TA database helped us to increase our knowledge about various indications and type of TA procedures that were performed in our current practice. We also believe that this database could serve as a model that other institutions can use to track service metrics.
Assuntos
Remoção de Componentes Sanguíneos/métodos , Bases de Dados Factuais , Remoção de Componentes Sanguíneos/estatística & dados numéricos , Bases de Dados Factuais/estatística & dados numéricos , Conjuntos de Dados como Assunto , Registros Eletrônicos de Saúde , Células-Tronco Hematopoéticas/citologia , Humanos , Troca PlasmáticaRESUMO
BACKGROUND: The irradiation of red blood cells (RBCs) causes damage of the RBC membrane with increased potassium (K) leak during storage compared with nonirradiated RBC units of similar age. A previous in vitro study showed a mean reduction of K of 94 ± 5% with a potassium adsorption filter (PAF). STUDY DESIGN AND METHODS: A prospective, single-center, nonblinded, randomized controlled trial (RCT) was designed to evaluate the safety and efficacy of transfusing irradiated RBC units with the PAF. Patients 18 years of age or older who received irradiated RBC units due to chemotherapy-induced anemia were randomly assigned to receive irradiated RBC units with the PAF (PAF group) or with the standard blood infusion set (control group). Primary outcome measures were safety and efficacy of the PAF (absolute change in hemoglobin [Hb] and K, respectively, in patient's blood values after transfusing the irradiated RBC units with or without the PAF). RESULTS: A total of 63 irradiated RBC units were transfused to 17 patients in the control group, and a total of 56 irradiated RBC units were transfused to 13 patients in the PAF group. The absolute change of Hb (9.3 ± 6.3 g/L vs. 8.1 ± 5.8 g/L; p = 0.3) and the absolute change of K (-0.01 ± 0.4 mmol/L vs. -0.01 ± 0.3 mmol/L; p = 0.2) were comparable between the two groups of the trial. CONCLUSION: The transfusion of 1 irradiated RBC unit with the PAF was as safe and efficacious as the transfusion of 1 irradiated RBC unit with the standard blood infusion set in patients with chemotherapy-induced anemia.
Assuntos
Transfusão de Eritrócitos/métodos , Eritrócitos/citologia , Filtração/métodos , Potássio/sangue , Adsorção , Adulto , Idoso , Anemia/induzido quimicamente , Anemia/terapia , Preservação de Sangue/métodos , Eritrócitos/efeitos da radiação , Feminino , Filtração/instrumentação , Filtração/normas , Hemoglobinas/análise , Humanos , Masculino , Pessoa de Meia-Idade , Potássio/isolamento & purificação , Estudos Prospectivos , Resultado do Tratamento , Adulto JovemRESUMO
OBJECTIVE: The purpose of our study was to evaluate the effects of the addition of melatonin and capecitabine on experimental pancreatic cancer. METHODS: Fifty Syrian hamsters were randomized in 5 groups: group 1: no tumor induction (control group); group 2: tumor induction with BOP [N-nitrosobis(2-oxopropyl) amine]; group 3: tumor induction with BOP and melatonin administration; group 4: tumor induction with BOP and capecitabine administration; and group 5: tumor induction with BOP and administration of combined capecitabine and melatonin therapy. The evaluation of pathological tumor evolution and oxidative stress markers in pancreatic tissue was carried out. RESULTS: All animals under BOP exposure presented poorly or moderately differentiated pancreatic adenocarcinoma associated with increased lipoperoxide levels and decreased antioxidant activity in pancreatic tissue. Pancreatic cancer was shown in only 66% of the capecitabine-treated group and 33% of melatonin-treated group (P < 0.05), most of them moderately differentiated adenocarcinoma. When capecitabine and melatonin were combined, a well-differentiated pancreatic adenocarcinoma was observed in 10% of animals. The beneficial effect was associated with a decrease in lipoperoxide levels and increased antioxidant activity in pancreatic tissue. CONCLUSIONS: The combined administration of capecitabine and melatonin provided an improvement in antioxidant status as well as a synergistic antitumoral effect in experimental pancreatic cancer.
Assuntos
Antimetabólitos Antineoplásicos/administração & dosagem , Desoxicitidina/análogos & derivados , Fluoruracila/análogos & derivados , Melatonina/administração & dosagem , Neoplasias Pancreáticas/tratamento farmacológico , Adenocarcinoma/induzido quimicamente , Adenocarcinoma/tratamento farmacológico , Adenocarcinoma/metabolismo , Adenocarcinoma/patologia , Animais , Antioxidantes/administração & dosagem , Antioxidantes/metabolismo , Capecitabina , Cricetinae , Desoxicitidina/administração & dosagem , Sinergismo Farmacológico , Quimioterapia Combinada , Fluoruracila/administração & dosagem , Peróxidos Lipídicos/metabolismo , Masculino , Mesocricetus , Nitrosaminas/toxicidade , Neoplasias Pancreáticas/induzido quimicamente , Neoplasias Pancreáticas/metabolismo , Neoplasias Pancreáticas/patologia , Pró-Fármacos/administração & dosagemRESUMO
BACKGROUND: Filtered PLT concentrates (PCs) were prepared in plasma pooling three (for children) or six buffy coats (BCs; for adults) after holding them a maximum of 4 hours (blood bags collected in the afternoon) or 18 hours (blood bags collected in the morning). STUDY DESIGN AND METHODS: With flow cytometry, PCs prepared after holding BCs 4 or 18 hours were compared. BCs removed from whole-blood donations in quadruple bag packs ("top-top") were held 4 or 18 hours before pooling them with a sterile connecting device. After the BCs were centrifuged, the supernatant was transferred through a BC filter (Autostop, Pall Medical) to a CLX bag. Samples for analysis were collected from the whole-blood bag, BCs, and PCs immediately after preparation and after 1, 3, 5, and 7 days of storage on a flat-bed agitator at 22 +/- 2 degrees C. The main PLT membrane glycoproteins (GPs, IIb-IIIa, IV, and Ibalpha), some of their ligands (fibrinogen, fibronectin, and VWF), activation-dependent antigens (CD62P and CD63), and procoagulant activity markers (annexin V and bound coagulation FV-Va) have been studied. RESULTS: In the 12 PCs (six pools of 3 units each group) studied, a minor increase in activation markers during preparation was observed. During the storage, a significant increase in the expression of GPIIb-IIIa, CD62P, CD63, annexin V, and FVa was measured. After 5 days of storage, only the percentage of PLTs with bound fibrinogen was significantly greater in PCs prepared after holding BCs for 4 hours. CONCLUSION: In PCs prepared after holding BCs 4 or 18 hours before pooling and filtering, only a minor significant difference in the percentage of PLTs with bound fibrinogen was found after 5 days of storage. This difference is probably of little, if any, transfusional significance.